Lightning bolt

Is the BMS CheckMate-227 trial a hit or miss in lung cancer?

Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227

July 25, 2019

Could targeting Regulatory T cells be a game changer?

Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.

March 18, 2019

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018

Can we use exosomes for immune monitoring?

One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…

June 21, 2018

Why don’t all cancer patients with a high TIL respond to immunotherapy?

We explore the importance of looking under the hood at various expression levels...

May 30, 2018

The PD-1 Gorilla is Back!

4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18

April 25, 2018

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018

Development of Next Generation CAR T cell therapies

A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers

May 14, 2018

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018

A new inhibitory checkpoint target hits the clinic

Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic

May 7, 2018

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018

Can TMB help select patients for lung cancer therapy or not?

A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?

April 23, 2018

To be or not to be…

Answering questions on the 1L NSCLC data presented at #AACR18

April 17, 2018

AACR18 Red and Green Flags in 1L NSCLC

A look at the latest 1L NSCLC trial readouts

April 16, 2018

AACR18 Day 2 Highlights

A look at the Class of 2018 new products in development - a hit or miss?

April 16, 2018

AACR18: Day 1 Cancer & Immunology Symposium

A look at some new - and very early - directions in CAR T cell therapies, especially in solid tumours.

April 15, 2018

An under-appreciated oncology drug class

How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?

April 10, 2018

The path to success in 1L NSCLC

Will the results from Merck's KEYNOTE-042 study change practice in 1L NSCLC?

April 9, 2018

AACR18 Preview 6: Beyond epacadostat and a look at early IO-IO combinations

Beyond the news that Incyte and Merck's epacadostat plus pembrolizumab combo failed to hit its endpoints in advanced melanoma, what other IO-IO combos should we turn to?

April 6, 2018

AACR18 Preview 5: is TGFβ an emerging cancer target?

A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination

April 4, 2018

AACR18 Preview 4: a look at new developments in a key tumour type

What's hot at #AACR18 in terms of data to watch out for in a certain tumour type?

April 3, 2018

Innate Pharma – converting science into the clinic

An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.

March 27, 2018

The squamous and non-squamous lung cancer race continues!

A look at the key lung cancer data expected at AACR18 and what to expect from the latest squamous NSCLC

March 21, 2018

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018